Lewis, Courtney
Keage, Megan
Watanabe, Miyuki
Schubiger, Danielle
Velakoulis, Dennis
Walterfang, Mark
Vogel, Adam P. http://orcid.org/0000-0002-3505-2631
Funding for this research was provided by:
Actelion Pharmaceuticals
National Health and Medical Research Council (1135683)
Article History
Received: 9 November 2019
Accepted: 6 June 2020
First Online: 19 June 2020
Compliance with Ethical Standards
:
: MW has received funding for research from, and has served on advisory boards for, Actelion Pharmaceuticals (manufacturer of Miglustat) and Vtesse Pharmaceuticals. AV is Chief Science Officer of Redenlab, who consult to a range pharmaceutical companies on clinical assessments. The authors declare that they have no other, including non-financial, conflict of interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Melbourne Health Human Research Ethics Committee (HREC reference number: QA2010057) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.